menu
    • menu

    Find Lumacaftor manufacturers, exporters & distributors on PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    8

    API Suppliers

    API Suppliers

    1

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    1

    EU WC

    EU WC

    0

    KDMF

    KDMF

    2

    NDC API

    NDC API

    0

    VMF

    NDC API

    8

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 24,833

    MARKET PLACE

    3

    API

    1

    FDF

    3INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    15

    FDF Dossiers

    FDF Dossiers

    5

    FDA Orange Book

    FDA (Orange Book)

    5

    Europe

    Europe

    5

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    4DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    107

    US Patents

    8

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    63

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    7,256

    Finished Drug Prices

    Listed Dossiers

    111 RELATED EXCIPIENT COMPANIES

    182EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 936727-05-8, Vx-809, Vx 809, Vx809, Vrt-826809, 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
    Molecular Formula
    C24H18F2N2O5
    Molecular Weight
    452.4  g/mol
    InChI Key
    UFSKUSARDNFIRC-UHFFFAOYSA-N
    FDA UNII
    EGP8L81APK
    Lumacaftor
    Lumacaftor is a drug used in combination with [DB08820] as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Mutations in the CFTR gene result in altered production, misfolding, or function of the CFTR protein and consequently abnormal fluid and ion transport across cell membranes. As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to infections, lung damage, pancreatic insufficiency, and malnutrition. Lumacaftor improves CF symptoms and underlying disease pathology by aiding the conformational stability of F508del-mutated CFTR proteins, preventing misfolding and resulting in increased processing and trafficking of mature protein to the cell surface. Results from clinical trials indicated that treatment with Orkambi (lumacaftor/ivacaftor) results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, increased weight gain, and improvements in CF symptoms. This data has been heavily scrutinized, however, with clinical trials showing only modest improvements despite a hefty yearly cost of $259,000 for Orkambi. Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute improvement of at least 5%. A wide variety of CFTR mutations correlate to the Cystic Fibrosis phenotype and are associated with differing levels of disease severity. The most common mutation, affecting approximately 70% of patients with CF worldwide, is known as F508del-CFTR, or delta-F508 (F508), in which a deletion in the amino acid phenylalanine at position 508 results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes. When used in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is specific for the management of CF in patients with delta-F508 mutations as it acts as a protein-folding chaperone, aiding the conformational stability of the mutated CFTR protein. Consequently, lumacaftor increases successful production of CFTR ion channels and the total number of receptors available for use at the cell membrane for fluid and ion transport. The next most common mutation, G551D, affecting 4-5% of CF patients worldwide, is characterized as a missense mutation, whereby there is sufficient amount of protein at the cell surface, but opening and closing mechanisms of the channel are altered. Treatment of patients with G551D and other rarer missense mutations is usually managed with [DB08820] (Kalydeco), as it aids with altered gating mechanisms by potentiating channel opening probability of CFTR protein. Prior to the development of lumacaftor and [DB08820] (Kalydeco), management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process. Approved for use by the Food and Drug Administration in July 2015 and by Health Canada in January 2016, Orkambi was the first combination product approved for the management of Cystic Fibrosis with delta-F508 mutations. Ivacaftor is manufactured and distributed by Vertex Pharmaceuticals.
    The mechanism of action of lumacaftor is as a Cytochrome P450 3A Inducer, and Cytochrome P450 2B6 Inducer, and Cytochrome P450 2C8 Inducer, and Cytochrome P450 2C9 Inducer, and Cytochrome P450 2C19 Inducer, and Cytochrome P450 2C8 Inhibitor, and Cytochrome P450 2C9 Inhibitor, and P-Glycoprotein Inducer, and P-Glycoprotein Inhibitor.
    1 2D Structure

    Lumacaftor

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid
    2.1.2 InChI
    InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)
    2.1.3 InChI Key
    UFSKUSARDNFIRC-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    EGP8L81APK
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Vx 809

    2. Vx-809

    3. Vx809

    2.3.2 Depositor-Supplied Synonyms

    1. 936727-05-8

    2. Vx-809

    3. Vx 809

    4. Vx809

    5. Vrt-826809

    6. 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic Acid

    7. Vrt 826809

    8. Vx-809 (lumacaftor)

    9. Egp8l81apk

    10. 3-(6-{[1-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-benzoicacid

    11. 3-(6-{[1-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-benzoic Acid

    12. 3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic Acid

    13. Lumacaftor (usan)

    14. 3-(6-{[1-(2,2-difluoro-2h-1,3-benzodioxol-5-yl)cyclopropane-1-carbonyl]amino}-3-methylpyridin-2-yl)benzoic Acid

    15. Lumacaftor [usan]

    16. 3-(6-(1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxamido)-3-methylpyridin-2-yl)benzoic Acid

    17. 3-(6-[[1-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino]-3-methyl-pyridin-2-yl)-benzoic Acid

    18. 3-(6-{[1-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-be

    19. 3-(6-{[1-(2,2-difluorobenzo[1,3]dioxol-5-yl)cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)benzoic Acid

    20. Benzoic Acid, 3-(6-(((1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl)carbonyl)amino)-3-methyl-2-pyridinyl)-

    21. Lumacaftor [inn]

    22. Lumacaftor [usan:inn]

    23. Unii-egp8l81apk

    24. Vx8

    25. Lumacaftor [mi]

    26. Lumacaftor (vx-809)

    27. Lumacaftor [who-dd]

    28. Lumacaftor(vx-809vx809)

    29. Mls006011120

    30. Schembl377028

    31. Gtpl7481

    32. Chembl2103870

    33. Lumacaftor [orange Book]

    34. Chebi:90951

    35. Dtxsid30239523

    36. Ex-a178

    37. Hms3655e05

    38. Orkambi Component Lumacaftor

    39. Amy14931

    40. Bcp02305

    41. Bdbm50289703

    42. Mfcd16659051

    43. S1565

    44. Zinc64033452

    45. Akos015920205

    46. Lumacaftor Component Of Orkambi

    47. Ccg-269253

    48. Cs-0479

    49. Db09280

    50. Pb19466

    51. Ncgc00346550-01

    52. Ncgc00346550-02

    53. Ncgc00346550-05

    54. Ac-23172

    55. As-31756

    56. Hy-13262

    57. Smr004702901

    58. Ft-0757817

    59. Sw219911-1

    60. A25628

    61. D10134

    62. J-690399

    63. Q6703005

    64. 3-(6-(1-(2,2-difluorobenzo(d) (1,3)dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic Acid

    65. 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) Cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic Acid

    66. 3-(6-{[1-(2,2-difluoro-2h-1,3-benzodioxol-5-yl)cyclopropane-1-carbonyl]amino}-3-methylpyridin-2-yl)benzoic Acid; Vx-809

    67. 3-(6-{[1-(2,2-difluorobenzo[1,3]dioxol-5-yl)cyclopropanecarbonyl]amino}-3-methyl-pyridin-2-yl)benzoic Acid

    2.4 Create Date
    2007-08-20
    3 Chemical and Physical Properties
    Molecular Weight 452.4 g/mol
    Molecular Formula C24H18F2N2O5
    XLogP34.4
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count5
    Exact Mass452.11837800 g/mol
    Monoisotopic Mass452.11837800 g/mol
    Topological Polar Surface Area97.8 Ų
    Heavy Atom Count33
    Formal Charge0
    Complexity776
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    When given in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene.

    FDA Label

    Treatment of cystic fibrosis

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Results from clinical trials indicated that treatment with Orkambi (lumacaftor/ [DB08820]) results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, reduced sweat chloride, increased weight gain, and improvements in CF symptoms and quality of life. Orkambi was not found to increase the QTc interval to any clinically relevant extent.

    5.2 FDA Pharmacological Classification
    5.2.1 Active Moiety
    LUMACAFTOR
    5.2.2 FDA UNII
    EGP8L81APK
    5.2.3 Pharmacological Classes
    Mechanisms of Action [MoA] - P-Glycoprotein Inhibitors
    5.3 ATC Code

    R07AX30

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    5.4 Absorption, Distribution and Excretion

    Absorption

    Following administration of Orkambi (lumacaftor/[DB08820]) with fat containing foods, peak plasma concentrations were reached at 4 hours (Tmax). It's recommended that Orkambi should be taken with fat-containing foods as they increase absorption of lumacaftor by approximately 2-fold, and[DB08820 by 3-fold.

    Route of Elimination

    Lumacaftor is primarily excreted unchanged in the feces (51%). A minimal amount of the parent compound and its metabolites are excreted in the urine.

    Volume of Distribution

    Following oral administration of 200 mg of lumacaftor every 24 hours to cystic fibrosis patients in a fed state for 28 days, the mean (+/-SD) for apparent volumes of distribution was 86.0 (69.8) L.

    Clearance

    The typical apparent clearance, CL/F (CV), of lumacaftor was estimated to be 2.38 L/hr.

    5.5 Metabolism/Metabolites

    Lumacaftor is mostly excreted unchanged in the feces and is not extensively metabolized. When metabolism does occur, oxidation and glucuronidation are the main processes involved.

    5.6 Biological Half-Life

    The half-life of lumacaftor is approximately 26 hours.

    5.7 Mechanism of Action

    Lumacaftor improves CF symptoms and underlying disease pathology by aiding the conformational stability of F508del-mutated CFTR, resulting in increased processing and trafficking of mature protein to the cell surface. More specifically, lumacaftor acts as a protein-folding chaperone, preventing misfolding of CFTR ion channels and consequent destruction during processing in the endoplasmic reticulum.

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1713465000,"product":"LUMACAFTOR (RUB - 0.9058)","address":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower","city":"Hyderabad","supplier":"APITORIA PHARMA PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"JSC PHARMASYNTEZ","customerCountry":"RUSSIA","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"2725200","totalValueFC":"88296.2","currency":"RUB","unitRateINR":2457792.8266666667,"date":"19-Apr-2024","totalValueINR":"7373378.48","totalValueInUsd":"88296.2","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"9245273","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1714415400,"product":"LUMACAFTOR BATCH NO: UZM0031123","address":"5\/502, GARDEN ESTATE,","city":"THANE, MAHARASHTRA.","supplier":"AMTEC HEALTHCARE PVT LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TRANSFARMA DIS TICARET ANONIM SIR,,","customerCountry":"TURKEY","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"2164526","totalValueFC":"25564.6","currency":"INR","unitRateINR":2134830.46,"date":"30-Apr-2024","totalValueINR":"2134830.46","totalValueInUsd":"25564.6","indian_port":"Bombay Air","hs_no":"29163190","bill_no":"9525591","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"5\/502, GARDEN ESTATE,, THANE, MAHARASHTRA.","customerAddress":""}]
    19-Apr-2024
    30-Apr-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Granulation

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Topical

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Looking for 936727-05-8 / Lumacaftor API manufacturers, exporters & distributors?

    Lumacaftor manufacturers, exporters & distributors 1

    42

    PharmaCompass offers a list of Lumacaftor API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lumacaftor manufacturer or Lumacaftor supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lumacaftor manufacturer or Lumacaftor supplier.

    PharmaCompass also assists you with knowing the Lumacaftor API Price utilized in the formulation of products. Lumacaftor API Price is not always fixed or binding as the Lumacaftor Price is obtained through a variety of data sources. The Lumacaftor Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Lumacaftor

    Synonyms

    936727-05-8, Vx-809, Vx 809, Vx809, Vrt-826809, 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

    Cas Number

    936727-05-8

    Unique Ingredient Identifier (UNII)

    EGP8L81APK

    About Lumacaftor

    Lumacaftor is a drug used in combination with [DB08820] as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Mutations in the CFTR gene result in altered production, misfolding, or function of the CFTR protein and consequently abnormal fluid and ion transport across cell membranes. As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to infections, lung damage, pancreatic insufficiency, and malnutrition. Lumacaftor improves CF symptoms and underlying disease pathology by aiding the conformational stability of F508del-mutated CFTR proteins, preventing misfolding and resulting in increased processing and trafficking of mature protein to the cell surface. Results from clinical trials indicated that treatment with Orkambi (lumacaftor/ivacaftor) results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, increased weight gain, and improvements in CF symptoms. This data has been heavily scrutinized, however, with clinical trials showing only modest improvements despite a hefty yearly cost of $259,000 for Orkambi. Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute improvement of at least 5%. A wide variety of CFTR mutations correlate to the Cystic Fibrosis phenotype and are associated with differing levels of disease severity. The most common mutation, affecting approximately 70% of patients with CF worldwide, is known as F508del-CFTR, or delta-F508 (F508), in which a deletion in the amino acid phenylalanine at position 508 results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes. When used in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is specific for the management of CF in patients with delta-F508 mutations as it acts as a protein-folding chaperone, aiding the conformational stability of the mutated CFTR protein. Consequently, lumacaftor increases successful production of CFTR ion channels and the total number of receptors available for use at the cell membrane for fluid and ion transport. The next most common mutation, G551D, affecting 4-5% of CF patients worldwide, is characterized as a missense mutation, whereby there is sufficient amount of protein at the cell surface, but opening and closing mechanisms of the channel are altered. Treatment of patients with G551D and other rarer missense mutations is usually managed with [DB08820] (Kalydeco), as it aids with altered gating mechanisms by potentiating channel opening probability of CFTR protein. Prior to the development of lumacaftor and [DB08820] (Kalydeco), management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process. Approved for use by the Food and Drug Administration in July 2015 and by Health Canada in January 2016, Orkambi was the first combination product approved for the management of Cystic Fibrosis with delta-F508 mutations. Ivacaftor is manufactured and distributed by Vertex Pharmaceuticals.

    Lumacaftor Manufacturers

    A Lumacaftor manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lumacaftor, including repackagers and relabelers. The FDA regulates Lumacaftor manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lumacaftor API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Lumacaftor manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Lumacaftor Suppliers

    A Lumacaftor supplier is an individual or a company that provides Lumacaftor active pharmaceutical ingredient (API) or Lumacaftor finished formulations upon request. The Lumacaftor suppliers may include Lumacaftor API manufacturers, exporters, distributors and traders.

    click here to find a list of Lumacaftor suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Lumacaftor USDMF

    A Lumacaftor DMF (Drug Master File) is a document detailing the whole manufacturing process of Lumacaftor active pharmaceutical ingredient (API) in detail. Different forms of Lumacaftor DMFs exist exist since differing nations have different regulations, such as Lumacaftor USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Lumacaftor DMF submitted to regulatory agencies in the US is known as a USDMF. Lumacaftor USDMF includes data on Lumacaftor's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lumacaftor USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Lumacaftor suppliers with USDMF on PharmaCompass.

    Lumacaftor WC

    A Lumacaftor written confirmation (Lumacaftor WC) is an official document issued by a regulatory agency to a Lumacaftor manufacturer, verifying that the manufacturing facility of a Lumacaftor active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lumacaftor APIs or Lumacaftor finished pharmaceutical products to another nation, regulatory agencies frequently require a Lumacaftor WC (written confirmation) as part of the regulatory process.

    click here to find a list of Lumacaftor suppliers with Written Confirmation (WC) on PharmaCompass.

    Lumacaftor NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lumacaftor as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Lumacaftor API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Lumacaftor as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Lumacaftor and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lumacaftor NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Lumacaftor suppliers with NDC on PharmaCompass.

    Lumacaftor GMP

    Lumacaftor Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Lumacaftor GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lumacaftor GMP manufacturer or Lumacaftor GMP API supplier for your needs.

    Lumacaftor CoA

    A Lumacaftor CoA (Certificate of Analysis) is a formal document that attests to Lumacaftor's compliance with Lumacaftor specifications and serves as a tool for batch-level quality control.

    Lumacaftor CoA mostly includes findings from lab analyses of a specific batch. For each Lumacaftor CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Lumacaftor may be tested according to a variety of international standards, such as European Pharmacopoeia (Lumacaftor EP), Lumacaftor JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lumacaftor USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search